Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 ,inter alia, to consider and approve 1. To consider and approve ....
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma has informed the exchanges that its Board of Directors will meet on Monday, May 19, 2025, in Mumbai. The key agenda items are to consider and approve the audited financial results (both standalone and consolidated) for the quarter and financial year ended March 31, 2025, and to consider recommending a dividend on equity shares for FY 2024-25, if any. The trading window for designated persons and their immediate relatives is already closed since April 1, 2025 and will remain closed until 48 hours after the results are announced (up to May 21, 2025). This is a standard advance intimation filed under SEBI Listing Regulations, with no actual financial numbers disclosed at this stage.
Investors should watch for the Q4 and FY25 results announcement on or after May 19, 2025. The possibility of a dividend recommendation is a mild positive signal for income-focused shareholders, but no concrete details are available yet.